Since the first announcement March 27 of the failed Phase 3 Diagnode-3 study, the company has initiated a strategic review including 1) discussions with possible partners, 2) reducing its Stockholm activities, and 3) moving its BioManufacturing Plant in Umeå towards GMP certification for production of recombinant products.

Ulf Hannelius steps down

As part of these changes, CEO Ulf Hannelius has decided to step down from his role.

“Ulf Hannelius has during his now 10 years as CEO at Diamyd, made a formidable contribution to the company’s development,” says Anders Essen-Möller, Chairman of the Board. “In particular the achievement of receiving both Fast Track Designation and Accelerated Approval potential for retogatein in the US are amazing. We all in Diamyd will miss him while looking for ways ahead to improve share value for shareholders while not forgetting our mission to help diabetes patients. Once Ulf departs, we really all wish him the best of luck, and hope to remain in close contact.”

“It has been the greatest privilege and an honor to spend the past 10 years working alongside an exceptionally talented and dedicated team at Diamyd Medical,” says Ulf Hannelius. “I look forward to continue supporting the company during the coming transition period.”

Anders Essen-Möller has been appointed Chief Executive Officer

The company also announces that Chairman Anders Essen-Möller has been appointed Chief Executive Officer. Vice Chairman Erik Nerpin has been appointed Chairman of the Board.